Our specialized units cover diverse therapeutic areas such as endocrinology, metabolic disorders, cardiology, gastroenterology, women’s health, dermatology, hematology, and nephrology.
Efficacy and safety of the ghrelin-O-acyltransferase inhibitor BI 1356225 in overweight/obesity: Data from two Phase I, randomised, placebo-controlled studies.
